非瓣膜性心房颤动患者导管消融术后抗凝策略的研究进展  

Anticoagulation Strategy in Patients with Nonvalvular Atrial Fibrillation after Catheter Ablation

作　　者：白金龙 李洪仕[1] 蔡衡[1] BAI Jinlong;LI Hongshi;CAI Heng(Department of Cardiology,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院心血管内科,天津300052

出　　处：《心血管病学进展》2021年第1期30-34,42,共6页Advances in Cardiovascular Diseases

摘　　要：非瓣膜性心房颤动患者导管消融术后的卒中预防策略尚存争议,现有指南大多推荐根据CHA2DS2-VASc评分制定抗凝策略,建议CHA2DS2-VASc评分≥2分的卒中高风险患者术后长期抗凝。但目前临床实践中,抗凝出血风险和患者依从性等问题仍待解决,对心房颤动患者术后卒中来源的剖析、卒中风险的全面评估以及个体化卒中预防策略的制定等问题仍有待进一步研究,现结合最新研究进展和观点对此问题展开综述。The prevention strategies of stroke in patients with non-valvular atrial fibrillation after catheter ablation are still controversial.Most existing guidelines recommend that anticoagulation strategies should be formulated according to CHA 2 DS 2-VASc score,and the patients whose CHA 2 DS 2-VASc score≥2 should receive long-term anticoagulation after ablation.However,the problems such as bleeding risk of anticoagulants and compliance of patients in clinical practice still need to be solved.It is still need to be further studied that the analysis on the source of stroke,the comprehensive assessment of stroke risk,and the formulation of individual stroke prevention strategies in atrial fibrillation patients after ablation.This paper will review this issue with the latest research progress and perspectives.

关 键 词：非瓣膜性心房颤动 导管消融 卒中 抗凝药物 

分 类 号：R541.75[医药卫生—心血管疾病]